EPIX Therapeutics, Inc. (formerly Advanced Cardiac Therapeutics, Inc.) is a medical device company that designs and manufactures a catheter-based system for the treatment of patients with AFIB. The Company's mission is to dramatically improve the treatment of AFIB through the introduction of products based on its proprietary catheter and generator system. EPIX's technology is the only system in the world to leverage three unique capabilities: temperature sensing and feedback, low irrigation flow rates and high resolution electrogram attenuation. The DiamondTempTM System is limited to investigational use in the United States. Founded in 2007, the company has pioneered the development of catheter ablation solutions for the treatment of atrial fibrillation and other arrhythmias. In 2014, the company brought in industry veteran Duke Rohlen as Chairman and CEO. Rohlen built a team that developed a novel technology, the DiamondTempTM radiofrequency ablation system, designed to treat patients with AFIB. In late 2017, the DiamondTempTM system received CE Marking for the device, and FDA approval of an investigational device evaluation application (IDE) to commence a 480-subject, multicenter, global, pivotal trial (Diamond-AF) to treat patients with paroxysmal AFIB. The company expects to complete the enrollment of this IDE study the end of 2018. The DiamondTemp™ is a medical device and is subject to applicable country and/or regional regulations. Atrial fibrillation is a condition in which the heart beats irregularly due to improper electrical impulses and is one of the most prevalent heart diseases globally, currently affecting an estimated six million people in the U.S. alone. The irregular heart beat can lead to increased risk of stroke and significant diminishment of quality of life for affected individuals. Catheter ablation has been demonstrated to be a safe, effective, and economic treatment for atrial fibrillation. The catheter ablation market is one of the fastest growing medical device markets today.